<!DOCTYPE html>
<html lang="en" data-theme="light">
<head><script src="/news/livereload.js?mindelay=10&amp;v=2&amp;port=1314&amp;path=news/livereload" data-no-instant defer></script>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lantern Pharma&#39;s AI-Driven Drug LP-300 Shows Promise in Treating Advanced Non-Small Cell Lung Cancer - Newswriter Business and Technology News</title>
    
    
    <meta name="description" content="Lantern Pharma&#39;s AI-driven LP-300 shows durable complete response in NSCLC trial, highlighting the potential of AI in transforming cancer treatment. Read more.">
    <meta name="keywords" content="news, breaking news, current events, analysis, journalism">
    <meta name="author" content="Newswriter Staff">
    
    
    <meta property="og:title" content="Lantern Pharma&#39;s AI-Driven Drug LP-300 Shows Promise in Treating Advanced Non-Small Cell Lung Cancer - Newswriter Business and Technology News">
    <meta property="og:description" content="Lantern Pharma&#39;s AI-driven LP-300 shows durable complete response in NSCLC trial, highlighting the potential of AI in transforming cancer treatment. Read more.">
    <meta property="og:type" content="article">
    <meta property="og:url" content="http://localhost:1314/news/news/202506/lantern-pharmas-ai-driven-drug-lp-300-shows-promise-in-treating-advanced-non-small-cell-lung-cancer/">
    
    <meta property="og:image" content="https://cdn.newsramp.app/genai/images/256/18/93a1be0d29e0e6149175ae01badea6fa.png">
    
    
    
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:title" content="Lantern Pharma&#39;s AI-Driven Drug LP-300 Shows Promise in Treating Advanced Non-Small Cell Lung Cancer - Newswriter Business and Technology News">
    <meta name="twitter:description" content="Lantern Pharma&#39;s AI-driven LP-300 shows durable complete response in NSCLC trial, highlighting the potential of AI in transforming cancer treatment. Read more.">
    
    
    <link rel="canonical" href="http://localhost:1314/news/news/202506/lantern-pharmas-ai-driven-drug-lp-300-shows-promise-in-treating-advanced-non-small-cell-lung-cancer/">
    
    
    <link href="https://cdn.jsdelivr.net/npm/daisyui@4.12.10/dist/full.min.css" rel="stylesheet" type="text/css" />
    <script src="https://cdn.tailwindcss.com"></script>
    
    
    
    <link rel="stylesheet" href="http://localhost:1314/news/css/main.min.a91d2a4774a8bf11b852a369bbb02ccccd66e5d4579847cf522248637572103e.css" integrity="sha256-qR0qR3SovxG4UqNpu7AszM1m5dRXmEfPUiJIY3VyED4=">
    
</head>
<body class="min-h-screen bg-base-100">
    
<div class="bg-white border-b border-gray-200">
  <div class="container mx-auto px-4 py-4">
    <div class="flex items-center justify-between">
      
      <a href="/" class="flex items-center">
        <img
          src="https://newswriter.ai/logo.svg"
          alt="Newswriter.ai"
          class="h-8 w-auto"
        />
      </a>

      
      <div class="relative">
        <div class="dropdown dropdown-end">
          <div tabindex="0" role="button" class="btn btn-primary">
            Write My Press Release
            <svg
              class="w-4 h-4 ml-1"
              fill="none"
              stroke="currentColor"
              viewBox="0 0 24 24"
            >
              <path
                stroke-linecap="round"
                stroke-linejoin="round"
                stroke-width="2"
                d="M19 9l-7 7-7-7"
              ></path>
            </svg>
          </div>
          <ul
            tabindex="0"
            class="dropdown-content menu bg-base-100 rounded-box z-[1] w-52 p-2 shadow"
          >
            <li>
              <a href="https://newswriter.ai" class="text-sm"
                >Write Press Release</a
              >
            </li>
          </ul>
        </div>
      </div>
    </div>
  </div>
</div>

    
    <main>
        

<div class="container mx-auto px-4 py-8">
  <div class="max-w-4xl mx-auto">
    
    <div class="text-sm mb-6">
      <a href="/" class="text-primary hover:underline">Home</a>
      <span class="text-gray-500 mx-2"> / </span>
      <span class="text-gray-500">Article</span>
    </div>

    
    <div class="mb-8">
      <h1
        class="text-4xl md:text-5xl font-bold text-base-content leading-tight mb-6"
      >
        Lantern Pharma&#39;s AI-Driven Drug LP-300 Shows Promise in Treating Advanced Non-Small Cell Lung Cancer
      </h1>

      
      <div class="border-b border-gray-200 pb-6 mb-8">
        <div class="flex items-center text-sm mb-4">
          <span class="text-primary font-semibold"> Newswriter Business and Technology News </span>
          <span class="text-gray-400 mx-2"> • </span>
          <span class="text-base-content opacity-70">
            June 16, 2025
          </span>
        </div>

        
        
        <a
          href="https://rss.investorbrandnetwork.com/iw/investornewsbreaks-lantern-pharma-inc-nasdaq-ltrn-reports-complete-response-in-advanced-nsclc-patient-in-harmonictm-trial/"
          target="_blank"
          class="inline-flex items-center text-primary hover:text-primary-focus underline font-medium"
        >
          Read Original Article →
        </a>
        
      </div>
    </div>

    
    
    <div class="mb-8">
      <img
        src="https://cdn.newsramp.app/genai/images/256/18/93a1be0d29e0e6149175ae01badea6fa.png"
        alt="Lantern Pharma&#39;s AI-Driven Drug LP-300 Shows Promise in Treating Advanced Non-Small Cell Lung Cancer"
        class="w-full h-96 object-cover rounded-lg shadow-lg mb-8"
      />
    </div>
    

    
    
    <div class="bg-base-00 rounded-lg mb-8">
      <h2 class="text-2xl font-bold text-base-content mb-4">Summary</h2>
      <div
        class="text-lg leading-relaxed mb-8 prose prose-lg max-w-none"
        style="color: var(--base-content)"
      >
        Lantern Pharma Inc. reports a significant clinical outcome from its Phase 2 HARMONIC(TM) trial, demonstrating the efficacy of LP-300 in treating advanced non-small cell lung cancer, particularly in never-smoker patients, marking a pivotal advancement in oncology and AI-driven drug development.
      </div>
    </div>
    

    
    <div class="mb-12">
      <h2 class="text-2xl font-bold text-base-content mb-6">Full Article</h2>
      <div
        class="prose prose-lg max-w-none leading-relaxed"
        style="color: var(--base-content)"
      >
        <div class="space-y-4">
          <p class='mb-4'><p>Lantern Pharma Inc. (NASDAQ: LTRN) has recently unveiled a promising clinical result from its Phase 2 HARMONIC(TM) trial, where its drug LP-300, in combination with standard chemotherapy, achieved a durable complete response in a 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC). This patient, who had previously undergone three lines of therapy without success, including treatments with Keytruda(R), radiation, and Tagrisso(R), saw a 57% reduction in tumor size initially, followed by the complete resolution of lung and adrenal lesions. Nearly two years after starting treatment, the patient remains progression-free, with no significant adverse reactions reported over 21 cycles of treatment.</p><p>This development is particularly significant as it addresses a critical unmet need in the treatment of never-smoker NSCLC patients who have exhausted targeted kinase therapy options. These patients represent a growing yet underserved segment with limited approved treatments. The success of LP-300, developed using Lantern Pharma's RADR(R) AI platform, highlights the transformative potential of artificial intelligence in oncology drug development. The RADR(R) platform utilizes over 200 billion oncology-focused data points and a library of more than 200 advanced machine learning algorithms to expedite the discovery and development of cancer therapies.</p><p>Lantern Pharma's breakthrough with LP-300 in the HARMONIC(TM) trial not only underscores the drug's potential to enhance outcomes for NSCLC patients but also exemplifies the company's innovative approach to reducing the cost and time associated with bringing new oncology treatments to market. With an average development timeline of 2-3 years and approximately $2.5 million per program, Lantern Pharma is establishing a new benchmark in the efficient and effective development of cancer therapies. This achievement offers hope to patients with limited treatment options and serves as a testament to the power of AI in revolutionizing drug development.</p></p>
        </div>
      </div>
    </div>

    
    
    <div class="bg-base-100 p-2 rounded-lg mb-8 text-sm text-gray-600">

      <img src="https://cdn.newsramp.app/ibn/qrcode/256/16/pintkF70.webp" alt="QR Code for Content Provenance" class="w-275 h-95 mb-4">

      
      <p>This story is based on an article that was registered on the blockchain. The original source content used for this article is located 
        at <a href="https://rss.investorbrandnetwork.com/iw/investornewsbreaks-lantern-pharma-inc-nasdaq-ltrn-reports-complete-response-in-advanced-nsclc-patient-in-harmonictm-trial/">InvestorBrandNetwork (IBN)</a></p>
      


      
      <p class="mt-5">Article Control ID: 84434</p>
       

    </div>
    

    
    <div class="text-center">
      <a href="/" class="btn btn-outline btn-lg">← Back to Home</a>
    </div>
  </div>
</div>

    </main>
    
    
<footer class="text-white">
  <div class="container mx-auto px-4 py-6">
    <div class="flex flex-col md:flex-row justify-between items-center gap-4">
      <div class="flex items-center gap-4">
        <p class="text-sm">
          Newswriter.ai © 2025 All Rights Reserved
        </p>
        <a
          href="https://newswriter.ai/privacy-policy"
          class="text-sm hover:text-cyan-200 transition-colors"
          >Privacy Policy</a
        >
        <a
          href="https://newswriter.ai/terms-of-service"
          class="text-sm hover:text-cyan-200 transition-colors"
          >Terms of Service</a
        >
      </div>
    </div>
  </div>
</footer>

</body>
</html>
